Table 1. Characteristics, HIV disease progression and ART treatment regimen of for study participants (HIV patients presenting in the advanced stages of HIV-infection—CD4 <200cells/mm3), in Dar es Salaam, Tanzania.
| Characteristics | Study sites | |||
|---|---|---|---|---|
| Buguruni | Tandale | Mbagala | All sites | |
| Sample size | 196 | 280 | 394 | 870 |
| Standard (control) arm | 99 | 140 | 197 | 436 |
| Intervention arm | 97 | 140 | 197 | 434 |
| Sex | ||||
| Male n(%) | 58 (29.6) | 105 (37.5) | 164 (41.6) | 327 (37.6) |
| Age at enrolment mean (SD) | 39.1 (10.4) | 37.4 (8.6) | 39.2(9.9) | 38.6 (9.7) |
| CD4 cells/mm3, median (min, max) | 52 (2, 189) | 57.5 (1, 199) | 47 (1, 199) | 52. (1, 199) |
| ARTa regimen initiated at enrolment n(%) | ||||
| d4T-containing regimen | 0 (0.00) | 0 (0.00) | 10(2.54) | 10 (1.15) |
| AZT-containing regimen | 68 (34.69) | 146 (52.14) | 100 (25.38) | 314 (36.09) |
| TDF -containing regimen | 125 (63.78) | 127 (45.36) | 269 (68.27) | 521 (59.89) |
| ABC -containing regimen* | 2 (1.02) | 5 (1.79) | 1 (0.25) | 8 (0.92) |
| Did not initiate on ART | 1 (0.51) | 2 (0.71) | 14 (3.55) | 17 (1.95) |
aART—Antiretroviral Therapy; ABC—abacavir; TDF—tenofovir disoproxil fumarate AZT—zidovudine; d4T –stavudine
*ABC is the nucleoside reverse transcriptase inhibitors (NRTIs) used as the second line drugs for adult and adolescents in Tanzania.